Literature DB >> 22483679

Analgesia targeting IB4-positive neurons in cancer-induced mechanical hypersensitivity.

Yi Ye1, Dongmin Dang, Chi T Viet, John C Dolan, Brian L Schmidt.   

Abstract

UNLABELLED: Cancer patients often suffer from pain and most will be prescribed μ-opioids. μ-opioids are not satisfactory in treating cancer pain and are associated with multiple debilitating side effects. Recent studies show that μ and δ opioid receptors are separately expressed on IB4 (-) and IB4 (+) neurons, which control thermal and mechanical pain, respectively. In this study we investigated IB4 (+) and IB4 (-) neurons in mechanical and thermal hypersensitivity in an orthotopic mouse oral cancer model. We used a δ opioid receptor agonist and a P2X(3) antagonist to target IB4 (+) neurons and to demonstrate that this subset plays a key role in cancer-induced mechanical allodynia, but not in thermal hyperalgesia. Moreover, selective removal of IB4 (+) neurons using IB4-saporin impacts cancer-induced mechanical but not thermal hypersensitivity. Our results demonstrate that peripherally administered pharmacological agents targeting IB4 (+) neurons, such as a selective δ-opioid receptor agonist or P2X(3) antagonist, might be useful in treating oral cancer pain. PERSPECTIVE: To clarify the mechanisms of oral cancer pain, we examined the differential role of IB4 (+) and IB4 (-) neurons. Characterization of these 2 subsets of putative nociceptors is important for further development of effective clinical cancer pain relief.
Copyright © 2012 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22483679      PMCID: PMC3786360          DOI: 10.1016/j.jpain.2012.01.006

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  63 in total

1.  Nerve growth factor links oral cancer progression, pain, and cachexia.

Authors:  Yi Ye; Dongmin Dang; Jianan Zhang; Chi T Viet; David K Lam; John C Dolan; Jennifer L Gibbs; Brian L Schmidt
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

2.  Distinct subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious thermal and mechanical stimuli.

Authors:  Daniel J Cavanaugh; Hyosang Lee; Liching Lo; Shannon D Shields; Mark J Zylka; Allan I Basbaum; David J Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

3.  Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway.

Authors:  D K Lam; B L Schmidt
Journal:  Pain       Date:  2010-03-01       Impact factor: 6.961

4.  Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion?

Authors:  Antonia Kolokythas; Darren P Cox; Nusi Dekker; Brian L Schmidt
Journal:  J Oral Maxillofac Surg       Date:  2010-04-03       Impact factor: 1.895

5.  Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).

Authors:  Bertrand Le Bourdonnec; Rolf T Windh; Lara K Leister; Q Jean Zhou; Christopher W Ajello; Minghua Gu; Guo-Hua Chu; Paul A Tuthill; William M Barker; Michael Koblish; Daniel D Wiant; Thomas M Graczyk; Serge Belanger; Joel A Cassel; Marina S Feschenko; Bernice L Brogdon; Steven A Smith; Michael J Derelanko; Steve Kutz; Patrick J Little; Robert N DeHaven; Diane L DeHaven-Hudkins; Roland E Dolle
Journal:  J Med Chem       Date:  2009-09-24       Impact factor: 7.446

6.  GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican.

Authors:  Oliver Bogen; Elizabeth K Joseph; Xiaojie Chen; Jon D Levine
Journal:  Eur J Neurosci       Date:  2008-06-28       Impact factor: 3.386

7.  JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.

Authors:  Ellen E Codd; John R Carson; Raymond W Colburn; Dennis J Stone; Christopher R Van Besien; Sui-Po Zhang; Paul R Wade; Elizabeth L Gallantine; Theo F Meert; Lory Molino; Shirley Pullan; Christine M Razler; Scott L Dax; Christopher M Flores
Journal:  J Pharmacol Exp Ther       Date:  2009-01-16       Impact factor: 4.030

8.  Dissociation of the opioid receptor mechanisms that control mechanical and heat pain.

Authors:  Grégory Scherrer; Noritaka Imamachi; Yu-Qing Cao; Candice Contet; Françoise Mennicken; Dajan O'Donnell; Brigitte L Kieffer; Allan I Basbaum
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

9.  Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  Pain       Date:  2010-03-04       Impact factor: 7.926

10.  RET signaling is required for survival and normal function of nonpeptidergic nociceptors.

Authors:  Judith P Golden; Masato Hoshi; Mohammed A Nassar; Hideki Enomoto; John N Wood; Jeffrey Milbrandt; Robert W Gereau; Eugene M Johnson; Sanjay Jain
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

View more
  19 in total

1.  The fundamental unit of pain is the cell.

Authors:  David B Reichling; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

2.  TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain.

Authors:  Cristian Acosta; Laiche Djouhri; Roger Watkins; Carol Berry; Kirsty Bromage; Sally N Lawson
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

3.  Neuronally produced versican V2 renders C-fiber nociceptors IB4 -positive.

Authors:  Oliver Bogen; Olaf Bender; Jana Löwe; Wolfgang Blenau; Beatrice Thevis; Wolfgang Schröder; Richard U Margolis; Jon D Levine; Ferdinand Hucho
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

4.  TRPV1 expression level in isolectin B₄-positive neurons contributes to mouse strain difference in cutaneous thermal nociceptive sensitivity.

Authors:  Kentaro Ono; Yi Ye; Chi T Viet; Dongmin Dang; Brian L Schmidt
Journal:  J Neurophysiol       Date:  2015-03-18       Impact factor: 2.714

Review 5.  Alleviating pain with delta opioid receptor agonists: evidence from experimental models.

Authors:  Sophie Berthiaume; Khaled Abdallah; Véronique Blais; Louis Gendron
Journal:  J Neural Transm (Vienna)       Date:  2020-03-18       Impact factor: 3.575

6.  Effect of anchoring 4-anilidopiperidines to opioid peptides.

Authors:  Ravil R Petrov; Yeon Sun Lee; Ruben S Vardanyan; Lu Liu; Shou-wu Ma; Peg Davis; Josephine Lai; Frank Porreca; Todd W Vanderah; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2013-04-03       Impact factor: 2.823

Review 7.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

8.  Mediation of Movement-Induced Breakthrough Cancer Pain by IB4-Binding Nociceptors in Rats.

Authors:  Joshua Havelin; Ian Imbert; Devki Sukhtankar; Bethany Remeniuk; Ian Pelletier; Jonathan Gentry; Alec Okun; Timothy Tiutan; Frank Porreca; Tamara E King
Journal:  J Neurosci       Date:  2017-04-24       Impact factor: 6.167

Review 9.  The Neurobiology of Cancer Pain.

Authors:  Brian L Schmidt
Journal:  J Oral Maxillofac Surg       Date:  2015-12       Impact factor: 1.895

Review 10.  The neurobiology of cancer pain.

Authors:  Brian L Schmidt
Journal:  Neuroscientist       Date:  2014-03-24       Impact factor: 7.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.